Prasad Raju 4

What Happened

• Prasad Raju, Chief Financial Officer of CRISPR Therapeutics (CRSP), reported an open‑market sale of 3,708 common shares on March 23, 2026 at $46.78 per share, generating $173,460. The filing also shows awards and derivative activity on March 20, 2026: an option grant for 38,499 shares, an RSU grant for 27,500 shares, and a reported exercise/conversion of 6,250 derivative shares (the filing shows both acquisition and disposition of the 6,250 shares on March 20). The 3,708‑share sale was reported as required to satisfy tax withholding in connection with RSU vesting (company policy), not a discretionary trade.

Key Details

• Sale: 3,708 shares sold on 2026-03-23 at $46.78; total proceeds $173,460.
• Grants on 2026-03-20:
  • Option/award: 38,499 shares (footnote F4) — vests 100% in 48 equal monthly installments starting April 20, 2026.
  • RSU award: 27,500 shares (footnote F5) — vests quarterly from Mar 20, 2027 through Mar 20, 2030.
• Prior RSU (25,000) from Mar 20, 2024 (footnote F6) had a vesting tranche on Mar 20, 2026; the sale to cover taxes (footnote F3) relates to RSU withholding.
• Exercise/Conversion: 6,250 derivative shares reported acquired and disposed on 2026-03-20 (no price reported); filing shows conversion/exercise activity but does not state sale price.
• Lock‑up: Some shares remain subject to an underwriter lock‑up tied to the issuer’s convertible senior notes due 2031 (footnote F1).
• Shares owned after the transactions: not specified in the excerpt provided.
• Filing timing: Form 4 was filed on 2026-03-24 covering trades on Mar 20 and Mar 23; no late filing flag indicated in the provided info.

Context

• The 3,708‑share sale is described in the filing as a mandatory sell‑to‑cover for tax withholding tied to RSU vesting (per company RSU Settlement Policy) — such sales are routine and not necessarily a signal of executive sentiment.
• The option grant vests monthly over four years; the RSU grant vests quarterly over four years — these are long‑term compensation awards.
• Derivative activity (exercise/conversion) is reported separately; when acquisition and disposition of the same number of shares are reported on the same date, it typically reflects conversion/exercise and an accompanying transfer or disposition, but the filing here provides no price detail for that leg.